Bill restricts abortion pill access, opens providers to broad liability

What it does

This bill requires the FDA to replace the current mifepristone (abortion pill) safety rules with an older, stricter version from 2011, and creates a federal lawsuit right allowing patients to sue telehealth providers and pharmacies for any health harm they attribute to the drug. It also bans all importation of mifepristone into the U.S., including by mail.

Why we flagged it

The bill's operative mechanism is twofold: it tightens FDA safety rules on mifepristone by reverting to a 2011 standard, and it creates a broad private right of action against providers. The title frames this as 'restoring safeguards,' but the actual effect is to restrict patient access and expose providers to litigation risk.

• Section 4 creates a federal private right of action for any health harm 'attributable, in whole or in part' to mifepristone use, allowing suits against providers for compensatory damages, punitive damages, and attorney fees. This is substantively unrelated to the REMS approval mechanism in Section 3 and introduces a novel federal tort regime.

What the text implies

• The 'attributable, in whole or in part' language in Section 4(b) sets an extremely low causation threshold—providers can be sued for any health event a patient claims is connected to the drug, even if the connection is speculative or the harm stems from other causes.
• Reverting to the 2011 REMS eliminates mail-order and telehealth dispensing that current rules permit, effectively restricting access to patients who can travel to in-person appointments, disproportionately affecting rural and low-income patients.
• The importation ban in Section 5 closes a pathway used by patients to obtain mifepristone from overseas suppliers, eliminating a workaround for those unable to access it domestically.
• The private right of action creates incentive for class-action litigation against providers, potentially driving telehealth and pharmacy providers out of the mifepristone market even if they comply with the REMS, due to litigation costs and liability exposure.
• The bill does not require proof of provider negligence or violation of the REMS—liability attaches to any harm a patient attributes to the drug, creating strict liability for providers.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Patients lose access to a medication the FDA has approved; those who do obtain it face a legal regime where providers can be sued for any claimed harm, creating chilling effects on provision. The 2011 REMS imposed stricter in-person dispensing and prescriber requirements, reducing access compared to current rules. The private right of action is unusually broad—it does not require proof of negligence or causation, only that harm is 'attributable, in whole or in part' to the drug, exposing provide

Who stands to gain

• litigation funders and plaintiff's attorneys (broad private right of action with punitive damages an
• anti-abortion advocacy organizations (if they fund or coordinate litigation)

Named in the bill

Secretary of Health and Human Services, FDA, mifepristone (Mifeprex, Korlym, RU-486), telehealth providers, pharmacies, Federal Food, Drug, and Cosmetic Act (Section 505-1, Section 801), Title 18 United States Code (Section 1462)

Where it stands

• May 6, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• May 6, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

3 lobbying clients named this bill on 4 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $1,950,000 in lobbying spend. A filing names 55 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 61% of bills with at least one filing.

Josh Hawley, the sponsor, reported $68,000 in PAC receipts in the 2026 cycle.

• American Fuel & Petrochemical Manufacturers — $1,160,000 on 1 filing
• Susan B Anthony List — $420,000 on 1 filing
• Cms Energy Corp — $370,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.